

ASX Release

Oventus FY2018 Annual General Meeting Recording

Brisbane, Australia 19th November 2018: Oventus Medical Ltd (ASX: OVN) is pleased to provide an audio recording of its FY2018 Annual General Meeting which includes an address given by Oventus Chairman, Dr Mel Bridges and a presentation by CEO, Dr Chris Hart and VP Marketing and Operations North America, Robin Randolph. The meeting concludes with a Q&A session.

To listen to the recording (available on the Oventus website under 'News & Media'):

<https://oventus.com.au/oventus-2018-agm-presentation-audio/>

The CEO's presentation to shareholders (available on the Oventus website under 'Investors'):

https://ovn.irmau.com/site/PDF/1242_0/AGMPresentation

The Chairman's address to shareholders (available on the Oventus website under 'Investors'):

https://ovn.irmau.com/site/PDF/1245_0/Chairman39sAddresstoShareholders

—ENDS—

For more information, please contact:

Dr Chris Hart, Managing Director and CEO: M: 0409 647 496

Jane Lowe, IR Department: M: 0411 117 774 or jane.lowe@irdepartment.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O₂Vent™ is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*